NASDAQ : IPSC
Century Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 266.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 266.18M |
| Enterprise Value | 185.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 181.08M |
| Shares Outstanding | 181.08M |
| Shares Change (YoY) | +67.40% |
| Shares Change (QoQ) | +6.36% |
| Owned by Insiders (%) | 1.69% |
| Owned by Institutions (%) | 55.88% |
| Float | 101.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.14 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.28 |
| Quick Ratio | 8.04 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -49.65% |
| Return on Assets (ROA) | -23.51% |
| Return on Invested Capital (ROIC) | -25.24% |
| Return on Capital Employed (ROCE) | -39.54% |
| Weighted Average Cost of Capital (WACC) | 11.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.41M |
| Employee Count | 78 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -68,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.67 |
| 52-Week Price Change | +154.90% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 2.10 |
| Relative Strength Index (RSI) | 44.71 |
| Average Volume (20 Days) | 1,061,102 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 29.13M |
| Short Previous Month | 29.22M |
| Short % of Shares Out | 16.09% |
| Short % of Float | 28.77% |
| Short Ratio (days to cover) | 37.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -78.93M |
| Operating Income | -107.52M |
| Pretax Income | -109.86M |
| Net Income | -109.79M |
| EBITDA | -95.22M |
| EBIT | -107.52M |
| Earnings Per Share (EPS) | -$0.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 119.71M |
| Total Debt | 38.67M |
| Net Cash | 81.05M |
| Net Cash Per Share | $0.45 |
| Equity (Book Value) | 232.35M |
| Book Value Per Share | 1.29 |
| Working Capital | 109.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -86.76M |
| Capital Expenditures | -1.33M |
| Depreciation & Amortization | 12.30M |
| Net Borrowing | n/a |
| Free Cash Flow | -88.09M |
| FCF Per Share | -$0.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -67.40% |
| Shareholder Yield | -67.40% |
| Earnings Yield | -52.11% |
| FCF Yield | -33.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.75 |
| Price Target Difference | 223.13% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.69 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |